Been a rough few years for Takeda. Vyvanse, their ADHD blockbuster fell off the patent cliff and Trintellix is also about to reach patent expiration. They've also had big clinical failures across multiple therapeutic areas and no other big breakthrough designations. They also wrote off their entire cell therapy division as a total loss in October and closed that down: https://www.fiercebiotech.com/biotech/takeda-taps-out-cell-t...
Been a rough few years for Takeda. Vyvanse, their ADHD blockbuster fell off the patent cliff and Trintellix is also about to reach patent expiration. They've also had big clinical failures across multiple therapeutic areas and no other big breakthrough designations. They also wrote off their entire cell therapy division as a total loss in October and closed that down: https://www.fiercebiotech.com/biotech/takeda-taps-out-cell-t...